Characterization of a novel, trastuzumab resistant human breast cancer cell line

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 2, 2010, Pages 627-640

  Barok, Mark ^a   Balazs, Margit ^b,c   Lazar, Viktoria ^b   Rakosy, Zsuzsa ^b,c   Toth, Eniko ^a   Treszl, Andrea ^b   Vereb, Gyorgy ^a   Colbern, Gail T ^d   Park, John W ^d   Szollosi, Janos ^a,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Array CGH; Breast tumor xenograft; Drug resistance; ErbB2 HER 2; Gene and protein expression; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL; ARTICLE; BREAST TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODEL; DRUG RESISTANCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; MOUSE MUTANT; ONCOGENE; PAGET NIPPLE DISEASE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MICE, SCID; ONCOGENES; RECEPTOR, ERBB-2;

EID: 77954466624     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Park JW, RM Neve, J Szollosi, CC Benz: Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 8, 392-401 (2008)
2. Friedlander E, M Barok, J Szollosi, G Vereb: ErbBdirected immunotherapy: antibodies in current practice and promising new agents. Immunol Lett 116, 126-140 (2008)
3. Bublil EM, Y Yarden: The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19, 124-134 (2007) (Pubitemid 46386405)
4. Landgraf R: HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Breast Cancer Res 9, 202 (2007)
5. Klapper LN, S Glathe, N Vaisman, NE Hynes, GC Andrews, M Sela, Y Yarden: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 96, 4995-5000 (1999) (Pubitemid 29214524)
6. Klapper LN, MH Kirschbaum, M Sela, Y Yarden: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77, 25-79 (2000) (Pubitemid 29439302)
7. Pierce JH, P Arnstein, E DiMarco, J Artrip, MH Kraus, F Lonardo, PP Di Fiore, SA Aaronson: Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 6, 1189-1194 (1991) (Pubitemid 21924207)
8. Slamon DJ, W Godolphin, LA Jones, JA Holt, SG Wong, DE Keith, WJ Levin, SG Stuart, J Udove, A Ullrich, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989) (Pubitemid 19147683)
9. Aigner A, H Juhl, C Malerczyk, A Tkybusch, CC Benz, F Czubayko: Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 20, 2101-2111 (2001) (Pubitemid 32424004)
10. Andrechek ER, WR Hardy, PM Siegel, MA Rudnicki, RD Cardiff, WJ Muller: Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci U S A 97, 3444-3449 (2000) (Pubitemid 30183322)
11. Moody SE, CJ Sarkisian, KT Hahn, EJ Gunther, S Pickup, KD Dugan, N Innocent, RD Cardiff, MD Schnall, LA Chodosh: Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451-461 (2002) (Pubitemid 41043950)
12. Slamon DJ, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram, J Baselga, L Norton: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-792 (2001) (Pubitemid 32222155)
13. Cobleigh MA, CL Vogel, D Tripathy, NJ Robert, S Scholl, L Fehrenbacher, JM Wolter, V Paton, S Shak, G Lieberman, DJ Slamon: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17, 2639-2648 (1999) (Pubitemid 29415219)
14. Burstein HJ, I Kuter, SM Campos, RS Gelman, L Tribou, LM Parker, J Manola, J Younger, U Matulonis, CA Bunnell, AH Partridge, PG Richardson, K Clarke, LN Shulman, EP Winer: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19, 2722-2730 (2001) (Pubitemid 32441378)
15. Pegram MD, A Lipton, DF Hayes, BL Weber, JM Baselga, D Tripathy, D Baly, SA Baughman, T Twaddell, JA Glaspy, DJ Slamon: Phase II study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16, 2659-2671 (1998) (Pubitemid 28363029)
16. Cardoso F, MJ Piccart, V Durbecq, A Di Leo: Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer 3, 247-257; discussion 258-249 (2002) (Pubitemid 35423144)
17. Tanner M, P Jarvinen, J Isola: Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61, 5345-5348 (2001) (Pubitemid 32694907)
18. Hudziak RM, GD Lewis, M Winget, BM Fendly, HM Shepard, A Ullrich: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9, 1165-1172 (1989) (Pubitemid 19071685)
19. Yakes FM, W Chinratanalab, CA Ritter, W King, S Seelig, CL Arteaga: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62, 4132-4141 (2002) (Pubitemid 34791085)
20. Lane HA, AB Motoyama, I Beuvink, NE Hynes: Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 12, S21-22 (2001) (Pubitemid 32750580)
21. Nagy P, A Jenei, S Damjanovich, TM Jovin, J Szolosi: Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 5, 255-271 (1999) (Pubitemid 30082145)
22. Sliwkowski MX, JA Lofgren, GD Lewis, TE Hotaling, BM Fendly, JA Fox: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26, 60-70 (1999) (Pubitemid 29411434)
23. Cuello M, SA Ettenberg, AS Clark, MM Keane, RH Posner, MM Nau, PA Dennis, S Lipkowitz: Downregulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61, 4892-4900 (2001) (Pubitemid 32691907)
24. Nagata Y, KH Lan, X Zhou, M Tan, FJ Esteva, AA Sahin, KS Klos, P Li, BP Monia, NT Nguyen, GN Hortobagyi, MC Hung, D Yu: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004) (Pubitemid 39485684)
25. Kono K, E Sato, H Naganuma, A Takahashi, K Mimura, H Nukui, H Fujii: Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res 10, 2538-2544 (2004) (Pubitemid 38445716)
26. Izumi Y, L Xu, E di Tomaso, D Fukumura, RK Jain: Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280 (2002) (Pubitemid 34260234)
27. Barok M, J Isola, Z Palyi-Krekk, P Nagy, I Juhasz, G Vereb, P Kauraniemi, A Kapanen, M Tanner, J Szollosi: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6, 2065-2072 (2007) (Pubitemid 47052497)
28. Clynes RA, TL Towers, LG Presta, JV Ravetch: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6, 443-446 (2000) (Pubitemid 30208162)
29. Motoyama AB, NE Hynes, HA Lane: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factorrelated peptides. Cancer Res 62, 3151-3158 (2002) (Pubitemid 34602408)
30. Lu Y, X Zi, M Pollak: Molecular mechanisms underlying IGF-I-induced attenuation of the growthinhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108, 334-341 (2004) (Pubitemid 37549597)
31. Price-Schiavi SA, S Jepson, P Li, M Arango, PS Rudland, L Yee, KL Carraway: Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99, 783-791 (2002) (Pubitemid 34575694)
32. Nagy P, E Friedlander, M Tanner, AI Kapanen, KL Carraway, J Isola, TM Jovin: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptinresistant, MUC4-expressing breast cancer cell line. Cancer Res 65, 473-482 (2005)
33. Pályi-Krekk Z, M Barok, J Isola, M Tammi, J Szöllõsi, P Nagy: Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalization in trastuzumab resistant breast cancer European Journal Of Cancer (2007)
34. Kono K, A Takahashi, F Ichihara, H Sugai, H Fujii, Y Matsumoto: Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62, 5813-5817 (2002) (Pubitemid 35204740)
35. Mimura K, K Kono, M Hanawa, M Kanzaki, A Nakao, A Ooi, H Fujii: Trastuzumab-mediated antibodydependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11, 4898-4904 (2005) (Pubitemid 41557210)
36. Kute T, CM Lack, M Willingham, B Bishwokama, H Williams, K Barrett, T Mitchell, JP Vaughn: Development of Herceptin resistance in breast cancer cells. Cytometry A 57, 86-93 (2004) (Pubitemid 38197598)
37. Ritter CA, M Perez-Torres, C Rinehart, M Guix, T Dugger, JA Engelman, CL Arteaga: Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network. Clin Cancer Res 13, 4909-4919 (2007) (Pubitemid 47294799)
38. Tanner M, AI Kapanen, T Junttila, O Raheem, S Grenman, J Elo, K Elenius, J Isola: Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3, 1585-1592 (2004) (Pubitemid 40136714)
39. Rennstam K, G Jonsson, M Tanner, PO Bendahl, J Staaf, AI Kapanen, R Karhu, B Baldetorp, A Borg, J Isola: Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genet Cytogenet 172, 95-106 (2007) (Pubitemid 46038865)
40. Marx C, C Berger, F Xu, C Amend, GK Scott, B Hann, JW Park, CC Benz: Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Dev Technol 4, 273-284 (2006) (Pubitemid 44083582)
41. Bosma GC, M Fried, RP Custer, A Carroll, DM Gibson, MJ Bosma: Evidence of functional lymphocytes in some (leaky) scid mice. J Exp Med 167, 1016-1033 (1988)
42. Balazs M, Z Adam, A Treszl, A Begany, J Hunyadi, R Adany: Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 46, 222-232 (2001) (Pubitemid 32899792)
43. Treszl A, A Ladanyi, Z Rakosy, Z Buczko, R Adany, M Balazs: Molecular cytogenetic characterization of a novel cell line established from a superficial spreading melanoma. Front Biosci 11, 1844-1853 (2006) (Pubitemid 43256427)
44. Snijders AM, N Nowak, R Segraves, S Blackwood, N Brown, J Conroy, G Hamilton, AK Hindle, B Huey, K Kimura, S Law, K Myambo, J Palmer, B Ylstra, JP Yue, JW Gray, AN Jain, D Pinkel, DG Albertson: Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 29, 263-264 (2001) (Pubitemid 33096449)
45. Pinkel D, R Segraves, D Sudar, S Clark, I Poole, D Kowbel, C Collins, WL Kuo, C Chen, Y Zhai, SH Dairkee, BM Ljung, JW Gray, DG Albertson: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20, 207-211 (1998) (Pubitemid 28455458)
46. Jain AN, TA Tokuyasu, AM Snijders, R Segraves, DG Albertson, D Pinkel: Fully automatic quantification of microarray image data. Genome Res 12, 325-332 (2002) (Pubitemid 34162999)
47. Bussey KJ, D Kane, M Sunshine, S Narasimhan, S Nishizuka, WC Reinhold, B Zeeberg, W Ajay, JN Weinstein: MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol 4, R27 (2003)
48. Rakosy Z, L Vizkeleti, S Ecsedi, Z Voko, A Begany, M Barok, Z Krekk, M Gallai, Z Szentirmay, R Adany, M Balazs: EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 121, 1729-1737 (2007) (Pubitemid 47417290)
49. Juhasz A, M Balazs, I Sziklay, Z Rakosy, A Treszl, G Repassy, R Adany: Chromosomal imbalances in laryngeal and hypopharyngeal cancers detected by comparative genomic hybridization. Cytometry A 67, 151-160 (2005) (Pubitemid 41437532)
50. Szollosi J, M Balazs, BG Feuerstein, CC Benz, FM Waldman: ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55, 5400-5407 (1995)
51. Rennstam K, M Ahlstedt-Soini, B Baldetorp, PO Bendahl, A Borg, R Karhu, M Tanner, M Tirkkonen, J Isola: Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 63, 8861-8868 (2003) (Pubitemid 38064066)
52. Ray ME, ZQ Yang, D Albertson, CG Kleer, JG Washburn, JA Macoska, SP Ethier: Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res 64, 40-47 (2004) (Pubitemid 38114080)
53. Courjal F, M Cuny, J Simony-Lafontaine, G Louason, P Speiser, R Zeillinger, C Rodriguez, C Theillet: Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 57, 4360-4367 (1997) (Pubitemid 27413447)
54. Dib A, J Adelaide, M Chaffanet, A Imbert, D Le Paslier, J Jacquemier, P Gaudray, C Theillet, D Birnbaum, MJ Pebusque: Characterization of the region of the short arm of chromosome 8 amplified in breast carcinoma. Oncogene 10, 995-1001 (1995)
55. Rummukainen JK, T Salminen, J Lundin, H Joensuu, JJ Isola: Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 81, 1545-1551 (2001) (Pubitemid 33064280)
56. Clark ES, B Brown, AS Whigham, A Kochaishvili, WG Yarbrough, AM Weaver: Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene 28, 431-444 (2009)
57. Paterson AL, JC Pole, KA Blood, MJ Garcia, SL Cooke, AE Teschendorff, Y Wang, SF Chin, B Ylstra, C Caldas, PA Edwards: Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event. Genes Chromosomes Cancer 46, 427-439 (2007) (Pubitemid 46449245)
58. Tornillo L, G Duchini, V Carafa, A Lugli, S Dirnhofer, D Di Vizio, A Boscaino, R Russo, C Tapia, R Schneider-Stock, G Sauter, L Insabato, LM Terracciano: Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest 85, 921-931 (2005) (Pubitemid 41021300)
59. Coon JS, E Marcus, S Gupta-Burt, S Seelig, K Jacobson, S Chen, V Renta, G Fronda, HD Preisler: Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8, 1061-1067 (2002) (Pubitemid 35177356)
60. Yarden Y, MX Sliwkowski: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137 (2001) (Pubitemid 33674041)
61. Mocanu MM, Z Fazekas, M Petras, P Nagy, Z Sebestyen, J Isola, J Timar, JW Park, G Vereb, J Szollosi: Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett 227, 201-212 (2005) (Pubitemid 41169934)
62. Palyi-Krekk Z, M Barok, J Isola, M Tammi, J Szollo si, P Nagy: Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 43, 2423-2433 (2007) (Pubitemid 47625976)
63. Palyi-Krekk Z, M Barok, T Kovacs, H Saya, O Nagano, J Szollosi, P Nagy: EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Lett 263, 231-242 (2008)
64. Fazekas Z, M Petras, A Fabian, Z Palyi-Krekk, P Nagy, S Damjanovich, G Vereb, J Szollosi: Two-sided fluorescence resonance energy transfer for assessing molecular interactions of up to three distinct species in confocal microscopy. Cytometry A 73, 209-219 (2008) (Pubitemid 351323750)
65. Barok M, M Balazs, P Nagy, Z Rakosy, A Treszl, E Toth, I Juhasz, JW Park, J Isola, G Vereb, J Szollosi: Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett 260, 198-208 (2008)
66. Osta WA, Y Chen, K Mikhitarian, M Mitas, M Salem, YA Hannun, DJ Cole, WE Gillanders: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64, 5818-5824 (2004) (Pubitemid 39095582)
67. Spizzo G, G Gastl, D Wolf, E Gunsilius, M Steurer, D Fong, A Amberger, R Margreiter, P Obrist: Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88, 574-578 (2003) (Pubitemid 36363367)
68. Al-Hajj M, MS Wicha, A Benito-Hernandez, SJ Morrison, MF Clarke: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100, 3983-3988 (2003) (Pubitemid 36418143)
69. Fabian A, M Barok, G Vereb, J Szollosi: Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry A 75, 67-74 (2009)